MOTS-C
Also known as: Mitochondrial ORF of the Twelve S rRNA Type-C
Molecular Identifiers
Overview
Mitochondrial peptide that improves insulin sensitivity and metabolic flexibility. Exercise mimetic properties. Acts on the AMPK pathway.
MRWQEMGYIFYPRKLR Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg Half-life
~4-8 hours
Administration Route
Subcutaneous
Category
Metabolic & Fat Loss
Mechanism of Action
- Activation of the AMPK pathway
- Improvement of insulin sensitivity
- Increased metabolic flexibility
- Exercise mimetic properties
- Regulation of folate and purine metabolism
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 5-15 mg per injection |
| Frequency | 2-3 times per week |
| Timing | Preferably pre-workout |
| Duration | 8-12 weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Mild gastrointestinal discomfort
- Transient fatigue
- Pain at injection site
Presentations & Preparation
Vials of MOTS-C found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: -20°C or refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on MOTS-C.
Related Peptides
5-Amino-1MQ
50 mg per capsule · 1-2 times daily
Adipotide
0.5-1 mg/kg per injection (subcutaneous) · Once daily
AICAR
50-150 mg per injection · 2-3 times per week
AOD 9604
300-600 mcg per injection · Once daily
Cagrilintide
1.2-4.5 mg per week (subcutaneous) · Once weekly
Dulaglutide
0.75-4.5 mg per week (subcutaneous) · Once weekly